Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids

Lange's handbook of chemistry

Lange, N. A., & Speight, J. G. (1992) · Choice Reviews Online · doi:10.5860/choice.30-1849 · Cited by 7,163

STRUCTURE AND FUNCTIONS OF THE 20S AND 26S PROTEASOMES

Coux, O., Tanaka, K., & Goldberg, A. L. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.004101 · Cited by 2,438

Structure of 20S proteasome from yeast at 2.4Å resolution

Groll, M., Ditzel, L., Löwe, J., Stock, D., Bochtler, M., Bartunik, H. D., & Huber, R. (1997) · Nature · doi:10.1038/386463a0 · Cited by 2,265

Crystal Structure of the 20 S Proteasome from the Archaeon T. acidophilum at 3.4 Å Resolution

Löwe, J., Stock, D., Jap, B. K., Zwickl, P., Baumeister, W. P., & Huber, R. (1995) · Science · doi:10.1126/science.7725097 · Cited by 1,540

Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids.

Kettner, C. A., & Shenvi, A. B. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42521-x · Cited by 294

The selective inhibition of thrombin by peptides of boroarginine.

Kettner, C. A., Mersinger, L. J., & Knabb, R. M. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44751-x · Cited by 254

Inhibition of serine proteases by peptidyl fluoromethyl ketones

Imperiali, B., & Abeles, R. H. (1986) · Biochemistry · doi:10.1021/bi00361a005 · Cited by 248

R-1-Acetamido-2-phenylethaneboronic acid. A specific transition-state analog for chymotrypsin

Matteson, D. S., Sadhu, K. M., & Lienhard, G. E. (1981) · Journal of the American Chemical Society · doi:10.1021/ja00407a051 · Cited by 153

Design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl .alpha.-ketobenzoxazoles, and the x-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzoxazole

Edwards, P. D., Meyer, E. F., Vijayalakshmi, J., Tuthill, P. A., Andisik, D., Gomes, B. C., & Strimpler, A. M. (1992) · Journal of the American Chemical Society · doi:10.1021/ja00031a046 · Cited by 145

Kinetic Characterization of the Chymotryptic Activity of the 20S Proteasome

Stein, R. L., Melandri, F. D., & Dick, L. R. (1996) · Biochemistry · doi:10.1021/bi952262x · Cited by 138

Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer

Adams, J. (2002) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(02)00343-5 · Cited by 141

Proteasome inhibitors as new anticancer drugs

Adams, J. (2002) · Current Opinion in Oncology · doi:10.1097/00001622-200211000-00007 · Cited by 140

Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia.

Tan, C., & Waldmann, T. A. (2002) · PubMed · Cited by 140

RELATIVE CONTRIBUTIONS OF THE FIVE MAJOR HUMAN CYTOCHROMES P450, 1A2, 2C9, 2C19, 2D6, AND 3A4, TO THE HEPATIC METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB

Uttamsingh, V., Lu, C., Miwa, G. T., & Gan, L.-S. L. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005710 · Cited by 139

Ubiquitin-Proteasome System and Proteasome Inhibition: New Strategies in Stroke Therapy

Wójcik, C., & Napoli, M. D. (2004) · Stroke · doi:10.1161/01.str.0000126891.93919.4e · Cited by 137

HUMAN METABOLISM OF THE PROTEASOME INHIBITOR BORTEZOMIB: IDENTIFICATION OF CIRCULATING METABOLITES

Pekol, T. M., Daniels, J. S., LaButti, J. N., Parsons, I., Nix, D., Baronas, E., Hsieh, F., Gan, L.-S. L., & Miwa, G. T. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002956 · Cited by 135

Bortezomib as a Potential Treatment for Prostate Cancer

Papandreou, C. N., & Logothetis, C. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2707 · Cited by 134

Synthesis of biologically active boron-containing compounds

Yang, F., Zhu, M., Zhang, J., & Zhou, H. (2017) · MedChemComm · doi:10.1039/c7md00552k · Cited by 133

Molecular recognition with boronic acids—applications in chemical biology

Whyte, G. F., Vilar, R., & Woscholski, R. (2013) · Journal of Chemical Biology · doi:10.1007/s12154-013-0099-0 · Cited by 132

Spotlight on ixazomib: potential in the treatment of multiple myeloma

Azab, A. K., Muz, B., Ghazarian, R., Ou, M., Luderer, M. J., & Kusdono, H. D. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s93602 · Cited by 134

Proteasome inhibitor bortezomib for the treatment of multiple myeloma

Cavo, M. (2006) · Leukemia · doi:10.1038/sj.leu.2404278 · Cited by 127

Benzoxaborole compounds for therapeutic uses: a patent review (2010- 2018)

Nocentini, A., Supuran, C. T., & Winum, J. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1473379 · Cited by 126

Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats

Yang, J., Wang, Z., Fang, Y., Jiang, J., Zhao, F., Wong, H. L., Bennett, M. K., Molineaux, C. J., & Kirk, C. J. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039164 · Cited by 128

The Proteasome

Elliott, P. J., & Ross, J. S. (2001) · American Journal of Clinical Pathology · doi:10.1309/44hw-5ycj-fllp-3r56 · Cited by 125

Proteasome Inhibitors: Recent Advances and New Perspectives In Medicinal Chemistry

Génin, E., Reboud‐Ravaux, M., & Vidal, J. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610790725515 · Cited by 124

The proteasome: a macromolecular assembly designed for controlled proteolysis

Zwickl, P., Voges, D., & Baumeister, W. P. (1999) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1999.0494 · Cited by 127

Recent developments with boron as a platform for novel drug design

Lesnikowski, Z. J. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1174687 · Cited by 121

Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria

Moreira, W., Ngan, G., Low, J. L., Poulsen, A., Chia, B. C. S., Ang, M. J. Y., Yap, A., Fulwood, J., Lakshmanan, U., Lim, J., et al. (2015) · mBio · doi:10.1128/mbio.00253-15 · Cited by 119

Proteasome deubiquitinases as novel targets for cancer therapy

D’Arcy, P., & Linder, S. T. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.07.011 · Cited by 122

Drug discovery in the next decade: innovation needed ASAP

Bennani, Y. L. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.06.004 · Cited by 120

Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: Insights into specificity and potency

Kim, K. B., Myung, J., Sin, N., & Crews, C. M. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00612-5 · Cited by 116

The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges

Tundo, G. R., Sbardella, D., Santoro, A. M., Coletta, A., Oddone, F., Grasso, G., Milardi, D., Lacal, P. M., Marini, S., Purrello, R., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107579 · Cited by 120

Iridium‐Catalyzed CH Activation versus Directed ortho Metalation: Complementary Borylation of Aromatics and Heteroaromatics

Hurst, T. E., Macklin, T. K., Becker, M., Hartmann, E., Kügel, W., Salle, J. P., Batsanov, A. S., Marder, T. B., & Snieckus, V. A. (2010) · Chemistry - A European Journal · doi:10.1002/chem.201000401 · Cited by 114

The Role of Microbiome in Brain Development and Neurodegenerative Diseases

Nandwana, V., Nandwana, N. K., Das, Y., Saito, M., Panda, T., Das, S., Almaguel, F. A., Hosmane, N. S., & Das, B. C. (2022) · Molecules · doi:10.3390/molecules27113402 · Cited by 117

Docking studies and model development of tea polyphenol proteasome inhibitors: Applications to rational drug design

Smith, D. M., Daniel, K. G., Wang, Z., Guida, W. C., Chan, T. H., & Dou, Q. P. (2003) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.10504 · Cited by 113

Efficient Hydrolysis of Organotrifluoroborates via Silica Gel and Water

Molander, G. A., Cavalcanti, L. N., Canturk, B., Pan, P., & Kennedy, L. E. (2009) · The Journal of Organic Chemistry · doi:10.1021/jo901441u · Cited by 112

Therapeutic targeting of cancer cell cycle using proteasome inhibitors

Rastogi, N., & Mishra, D. P. (2012) · Cell Division · doi:10.1186/1747-1028-7-26 · Cited by 110

Structure, Dynamics and Function of the 26S Proteasome

Mao, Y. (2020) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-030-58971-4_1 · Cited by 111

A Beginner's Guide to NF‐κB Signaling Pathways

Delhalle, S., Blasius, R., Dicato, M. A., & Diederich, M. F. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1329.002 · Cited by 108

Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells

Codony-Servat, J., Tapia, M. A., Bosch, M., Oliva, C., Domingo-Domenech, J., Mellado, B., Rolfe, M., Ross, J. S., Gascon, P., Rovira, A., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0147 · Cited by 104

Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons

Staff, N. P., Podratz, J. L., Grassner, L., Lange, M. L. B., Paz, J., Knight, A. M., Loprinzi, C. L., Trushina, E. V., & Windebank, A. J. (2013) · NeuroToxicology · doi:10.1016/j.neuro.2013.09.001 · Cited by 103

Bivalency as a principle for proteasome inhibition

Loidl, G., Groll, M., Musiol, H., Huber, R., & Moroder, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5418 · Cited by 103

The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection

Basler, M., Lauer, C., Beck, U., & Groettrup, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901596 · Cited by 100

Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen

Yip, K. W., Mao, X., Au, P. Y. B., Hedley, D. W., Chow, S., Dalili, S., Mocanu, J. D., Bastianutto, C., Schimmer, A., & Liu, F.-F. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0536 · Cited by 99

Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment

Yang, H., Landis‐Piwowar, K. R., Chen, D., Milacic, V., & Dou, Q. P. (2008) · Current Protein and Peptide Science · doi:10.2174/138920308784533998 · Cited by 99

Structure-Based Design of β1i or β5i Specific Inhibitors of Human Immunoproteasomes

de Bruin, G., Huber, E. M., Xin, B., van Rooden, E. J., Ayed, K. A., Kim, K., Kisselev, A. F., Driessen, C., van der Stelt, M., van der Marel, G. A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500716s · Cited by 103

Proteasome Regulators: Activators and Inhibitors

Huang, L., & Chen, C. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787581860 · Cited by 98

Cap-independent Nrf2 translation is part of a lipoic acid-stimulated detoxification stress response

Shay, K. P., Michels, A. J., Li, W., Kong, A. T., & Hagen, T. M. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.04.002 · Cited by 97

Alkynylboranes: A Practical Approach by Zinc‐Catalyzed Dehydrogenative Coupling of Terminal Alkynes with 1,8‐Naphthalenediaminatoborane

Tsuchimoto, T., Utsugi, H., Sugiura, T., & Horio, S. (2014) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201400767 · Cited by 97

Advances in and applications of proteasome inhibitors

Moore, B. S., Eustáquio, A. S., & McGlinchey, R. P. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.06.033 · Cited by 100

Peptidase inhibitors in the MEROPS database

Rawlings, N. D. (2010) · Biochimie · doi:10.1016/j.biochi.2010.04.013 · Cited by 96

Natural products from thioester reductase containing biosynthetic pathways

Mullowney, M. W., McClure, R. A., Robey, M. T., Kelleher, N. L., & Thomson, R. J. (2018) · Natural Product Reports · doi:10.1039/c8np00013a · Cited by 95

Synthesis and biological activity of α-aminoboronic acids, amine-carboxyboranes and their derivatives

Dembitsky, V. M., & Srebnik, M. (2003) · Tetrahedron · doi:10.1016/s0040-4020(02)01618-6 · Cited by 95

Proteasome activation delays aging in vitro and in vivo

Chondrogianni, N., Sakellari, M., Lefaki, M., Papaevgeniou, N., & Gonos, E. S. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.03.031 · Cited by 94

α‐Amido boronic acids: A synthetic challenge and their properties as serine protease inhibitors

Matteson, D. S. (2007) · Medicinal Research Reviews · doi:10.1002/med.20105 · Cited by 93

Ionizing radiation affects 26s proteasome function and associated molecular responses, even at low doses

Pajonk, F., & McBride, W. H. (2001) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(01)00311-5 · Cited by 95

Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib

Liu, F., Agrawal, S. G., Movasaghi, Z., Wyatt, P. B., Rehman, I. U., Gribben, J. G., Newland, A. C., & Jia, L. (2008) · Blood · doi:10.1182/blood-2008-04-150227 · Cited by 92

Bortezomib in the treatment of AL amyloidosis: targeted therapy?

Sitia, R., Palladini, G. O., & Merlini, G. (2007) · Haematologica · doi:10.3324/haematol.12136 · Cited by 91

Carfilzomib: A Novel Second-Generation Proteasome Inhibitor

Khan, M. L., & Stewart, A. K. (2011) · Future Oncology · doi:10.2217/fon.11.42 · Cited by 91

Synthesis and Pharmacology of Proteasome Inhibitors

Rentsch, A., Landsberg, D., Brodmann, T., Bülow, L., Girbig, A., & Kalesse, M. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201207900 · Cited by 91

Molecular shredders: how proteasomes fulfill their role

Groll, M., & Clausen, T. (2003) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2003.10.005 · Cited by 91

Molecular Mechanisms of the Teratogenic Effects of Thalidomide

Asatsuma‐Okumura, T., Ito, T., & Handa, H. (2020) · Pharmaceuticals · doi:10.3390/ph13050095 · Cited by 88

Proteasome inhibitors: Dozens of molecules and still counting

de Bettignies, G., & Coux, O. (2010) · Biochimie · doi:10.1016/j.biochi.2010.06.023 · Cited by 88

Activity-Based Profiling Reveals Reactivity of the Murine Thymoproteasome-Specific Subunit β5t

Florea, B. I., Verdoes, M., Li, N., van der Linden, W. A., Geurink, P. P., van den Elst, H., Hofmann, T., de Ru, A., van Veelen, P. A., Tanaka, K., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.027 · Cited by 89

Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism

Ying, W., Wang, P.-X., Aaron, K. J., Basnayake, K., & Sanders, P. W. (2010) · Blood · doi:10.1182/blood-2010-08-302505 · Cited by 84

Caretaker or undertaker? The role of the proteasome in aging

Gaczynska, M. E., Osmulski, P. A., & Ward, W. F. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(00)00246-3 · Cited by 83

Design, Synthesis, and Biological Activity of Boronic Acid-Based Histone Deacetylase Inhibitors

Suzuki, N., Suzuki, T., Ota, Y., Nakano, T., Kurihara, M., Okuda, H., Yamori, T., Tsumoto, H., Nakagawa, H., & Miyata, N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900125m · Cited by 81

Acylboranes: synthetic strategies and applications

Scharnagl, F. K., Bose, S. K., & Marder, T. B. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob02425d · Cited by 80

New agents in cancer clinical trials

Adams, J., & Elliott, P. J. (2000) · Oncogene · doi:10.1038/sj.onc.1204088 · Cited by 80

Small-Molecule Inhibitors of the p53-MDM2 Interaction

Vu, B. T., & Vassilev, L. T. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_110 · Cited by 82

Aaptamine, an alkaloid from the sponge Aaptos suberitoides, functions as a proteasome inhibitor

Tsukamoto, S., Yamanokuchi, R., Yoshitomi, M., Sato, K., Ikeda, T., Rotinsulu, H., Mangindaan, R. E. P., de Voogd, N. J., van Soest, R. W. M., & Yokosawa, H. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.029 · Cited by 77

Chemical and Biological Evaluation of Dipeptidyl Boronic Acid Proteasome Inhibitors for Use in Prodrugs and Pro-Soft Drugs Targeting Solid Tumors

Milo, L. J., Lai, J. H.-S., Wu, W., Liu, Y., Maw, H. H., Li, Y., Jin, Z., Shu, Y., Poplawski, S. E., Wu, Y. H., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200460q · Cited by 76

α-Aminoboronates: recent advances in their preparation and synthetic applications

Ming, W., Soor, H. S., Liu, X., Trofimova, A., Yudin, A. K., & Marder, T. B. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00423a · Cited by 74

Green tea polyphenols in the prevention of colon cancer

Kumar, N. B. (2006) · Frontiers in bioscience · doi:10.2741/2233 · Cited by 74

Peptido Sulfonyl Fluorides as New Powerful Proteasome Inhibitors

Brouwer, A. J., Jonker, A. M., Werkhoven, P. R., Kuo, E., Li, N., Gallastegui, N., Kemmink, J., Florea, B. I., Groll, M., Overkleeft, H. S., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301443r · Cited by 74

Site-Specific Proteasome Inhibitors

Kisselev, A. F. (2021) · Biomolecules · doi:10.3390/biom12010054 · Cited by 76

The proteasome: a novel target for anticancer therapy

Montagut, C. O., Rovira, A., & Albanell, J. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0176-8 · Cited by 73

Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies

Jackson, G. H., Einsele, H., Moreau, P., & Miguel, J. F. S. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.10.001 · Cited by 73

Iridium‐Catalyzed Chemoselective and Enantioselective Hydrogenation of (1‐Chloro‐1‐Alkenyl) Boronic Esters

Smilović, I. G., Casas‐Arcé, E., Roseblade, S. J., Nettekoven, U., Zanotti‐Gerosa, A., Kovačevič, M., & Časar, Z. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201106262 · Cited by 73

Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib

Nerini‐Molteni, S., Ferrarini, M., Cozza, S., Caligaris‐Cappio, F., & Sitia, R. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07066.x · Cited by 72

The persisting challenge of selective and specific proteasome inhibition

Groll, M., Huber, R., & Moroder, L. (2008) · Journal of Peptide Science · doi:10.1002/psc.1107 · Cited by 72

CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice.

Sun, J., Nam, S., Lee, C., Li, B., Coppola, D., Hamilton, A. D., Dou, Q. P., & Sebti, S. M. (2001) · PubMed · Cited by 72

Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib

Williamson, M. J., Blank, J. L., Bruzzese, F. J., Cao, Y., Daniels, J. S., Dick, L. R., LaButti, J. N., Mazzola, A. M., Patil, A. D., Reimer, C., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0185 · Cited by 71

Boron Therapeutics on the Horizon

Groziak, M. P. (2001) · American Journal of Therapeutics · doi:10.1097/00045391-200109000-00005 · Cited by 69

Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma

Chang, X.-B., Zhu, Y., Shi, C., & Stewart, A. K. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt142 · Cited by 72

Schistosoma mansoni: Functional proteasomes are required for development in the vertebrate host

Guerra‐Sá, R., Castro‐Borges, W., Evangelista, E. A., Kettelhut, Í. D. C., & Rodrigues, V. (2005) · Experimental Parasitology · doi:10.1016/j.exppara.2005.01.002 · Cited by 69

Proteasome Inhibitors with Photocontrolled Activity

Hansen, M. J., Velema, W. A., de Bruin, G., Overkleeft, H. S., Szymański, W., & Feringa, B. L. (2014) · ChemBioChem · doi:10.1002/cbic.201402237 · Cited by 68

Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives

Schrezenmeier, E. V., Jayne, D. R. W., & Dörner, T. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017040367 · Cited by 68

Heterocycles and Medicine

Wu, Y. (2012) · Progress in heterocyclic chemistry · doi:10.1016/b978-0-08-096807-0.00001-4 · Cited by 67

Targeting Proteasomal Pathways by Dietary Curcumin for Cancer Prevention and Treatment

Hasima, N., & Aggarwal, B. B. (2014) · Current Medicinal Chemistry · doi:10.2174/09298673113206660135 · Cited by 67

Retroviruses Have Differing Requirements for Proteasome Function in the Budding Process

Ott, D. E., Coren, L. V., Sowder, R. C., Adams, J., & Schubert, U. (2003) · Journal of Virology · doi:10.1128/jvi.77.6.3384-3393.2003 · Cited by 67

Proteasome Inhibitors in the Treatment of B-Cell Malignancies

Schenkein, D. P. (2002) · Clinical Lymphoma · doi:10.3816/clm.2002.n.011 · Cited by 65

Conjugation and deconjugation of ubiquitin regulating the destiny of proteins

Baek, K. (2003) · Experimental & Molecular Medicine · doi:10.1038/emm.2003.1 · Cited by 64

Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer

Molineaux, S. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0853 · Cited by 68

Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors

Kloss, A., Meiners, S., Ludwig, A., & Dahlmann, B. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp217 · Cited by 63

Molecular Basis for Proline- and Arginine-Rich Peptide Inhibition of Proteasome

Anbanandam, A., Albarado, D. C., Tı̂rziu, D., Simons, M., & Veeraraghavan, S. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.09.021 · Cited by 62

Distinct Specificities of Mycobacterium tuberculosis and Mammalian Proteasomes for N-Acetyl Tripeptide Substrates

Lin, G., Tsu, C. A., Dick, L. R., Zhou, X. K., & Nathan, C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805324200 · Cited by 61

Proteasome inhibition improves diaphragm function in congestive heart failure rats

van Hees, H. W. H., Li, Y.-P., Ottenheijm, C. A. C., Jin, B., Pigmans, C. J. C., Linkels, M., Dekhuijzen, P. N. R., & Heunks, L. M. A. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00035.2008 · Cited by 61

Proteasome inhibitors in lung cancer

Scagliotti, G. V. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.12.001 · Cited by 61

Induction of G1 Arrest and Apoptosis in Human Jurkat T Cells by Pentagalloylglucose through Inhibiting Proteasome Activity and Elevating p27Kip1, p21Cip1/WAF1, and Bax Proteins

Chen, W. J., & Lin, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m212390200 · Cited by 61

The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models

Williamson, M. J., Silva, M. D., Terkelsen, J., Robertson, R., Yu, L., Xia, C. Q., Hatsis, P., Bannerman, B. M., Babcock, T., Cao, Y., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0239 · Cited by 60

Exploiting nature's rich source of proteasome inhibitors as starting points in drug development

Graewert, M. A., & Groll, M. (2011) · Chemical Communications · doi:10.1039/c1cc15273d · Cited by 62

Equine Infectious Anemia Virus and the Ubiquitin-Proteasome System

Ott, D. E., Coren, L. V., Sowder, R. C., Adams, J., Nagashima, K., & Schubert, U. (2002) · Journal of Virology · doi:10.1128/jvi.76.6.3038-3044.2002 · Cited by 60

The proteasome: A supramolecular assembly designed for controlled proteolysis

Zwickl, P., Seemüller, E., Kapelari, B., & Baumeister, W. (2001) · Advances in protein chemistry · doi:10.1016/s0065-3233(01)59006-3 · Cited by 60

Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer

Fahy, B. N., Schlieman, M. G., Virudachalam, S., & Bold, R. J. (2003) · Journal of Surgical Research · doi:10.1016/s0022-4804(03)00201-4 · Cited by 58

Proteasome Inhibitors: Complex Tools for a Complex Enzyme

Bogyo, M. S., & Wang, E. W. (2002) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-59414-4_8 · Cited by 58

Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells

GARDNER, R. C., Assinder, S. J., Christie, G., MASON, G. G. F., Markwell, R. E., Wadsworth, H., MCLAUGHLIN, M., King, R. J., Chabot‐Fletcher, M., Breton, J., et al. (2000) · Biochemical Journal · doi:10.1042/bj3460447 · Cited by 58

Piperlongumine induces inhibition of the ubiquitin–proteasome system in cancer cells

Jarvius, M., Fryknäs, M., D’Arcy, P., Sun, C., Rickardson, L., Gullbo, J., Haglund, C., Nygren, P., Linder, S. T., & Larsson, R. L. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.01.017 · Cited by 57

Metal-Catalyzed Hydroboration and Diboration of Thiocarbonyls and Vinyl Sulfides

Carter, C. A. G., Vogels, C. M., Harrison, D. J., Gagnon, M.-H., Norman, D. W., Langler, R. F., Baker, R. T. K., & Westcott, S. A. (2001) · Organometallics · doi:10.1021/om010135t · Cited by 57

One-shot NMR analysis of microbial secretions identifies highly potent proteasome inhibitor

Stein, M., Beck, P., Kaiser, M., Dudler, R., Becker, C. F. W., & Groll, M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211423109 · Cited by 57

ChemInform Abstract: Potent and Selective Inhibitors of the Proteasome: Dipeptidyl Boronic Acids.

Adams, J., Behnke, M. L., CHEN, S., Cruickshank, A., Dick, L. R., Grenier, L., Klunder, J. M., MA, Y. ‐., Plamondon, L., & Stein, R. L. (1998) · ChemInform · doi:10.1002/chin.199821191 · Cited by 1

α-Aminoboronic Acid Moieties in Boro Dipeptides Modulate Proteasome Subunit Selectivity and Provide Access to Compounds with Potent Anticancer and Anti-Inflammatory Activity

Benedik, N. S., Šterman, A., Smrdel, L., Pajk, S., Gobec, S., Časar, Z., Gobec, M., & Sosič, I. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02548 · Cited by 3

Synthesis, in Vitro and in Vivo Biological Evaluation, and Comprehensive Understanding of Structure−Activity Relationships of Dipeptidyl Boronic Acid Proteasome Inhibitors Constructed from β-Amino Acids

Zhu, Y., Wu, G., Zhu, X., Ma, Y., Zhao, X., Li, Y., Yuan, Y., Yang, J., Yu, S., Shao, F., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1009742 · Cited by 38

Synthesis, in Vitro and in Vivo Biological Evaluation, Docking Studies, and Structure−Activity Relationship (SAR) Discussion of Dipeptidyl Boronic Acid Proteasome Inhibitors Composed of β-Amino Acids

Zhu, Y., Zhu, X., Wu, G., Ma, Y., Li, Y., Zhao, X., Yuan, Y., Yang, J., Yu, S., Shao, F., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901407s · Cited by 39

Design, Synthesis, Biological Evaluation, and Structure−Activity Relationship (SAR) Discussion of Dipeptidyl Boronate Proteasome Inhibitors, Part I: Comprehensive Understanding of the SAR of α-Amino Acid Boronates

Zhu, Y., Zhao, X., Zhu, X., Wu, G., Li, Y., Ma, Y., Yuan, Y., Yang, J., Hu, Y., Ai, L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9005093 · Cited by 75